

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM838333

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
HEMOSTATIX MEDICAL TECHNOLOGIES, LLC		01/01/2022	Limited Liability Company: TENNESSEE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	C2DX, INC.		
<b>Street Address:</b>	555 E. Eliza Street, Suite A		
<b>City:</b>	Schoolcraft		
<b>State/Country:</b>	MICHIGAN		
<b>Postal Code:</b>	49087		
<b>Entity Type:</b>	Corporation: MICHIGAN		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2128414	HEMOSTATIX	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7343722940		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	17343722933		
<b>Email:</b>	trademarks@varnumlaw.com		
<b>Correspondent Name:</b>	Staci R. DeRegnaucourt		
<b>Address Line 1:</b>	101 North Main Street, Suite 525		
<b>Address Line 4:</b>	Ann Arbor, MICHIGAN 48104		
<b>NAME OF SUBMITTER:</b>	Staci R. DeRegnaucourt		
<b>SIGNATURE:</b>	/Staci R. DeRegnaucourt/		
<b>DATE SIGNED:</b>	09/11/2023		
<b>Total Attachments: 5</b>			
source=Hemostatix to C2DX Assignment#page1.tif			
source=Hemostatix to C2DX Assignment#page2.tif			
source=Hemostatix to C2DX Assignment#page3.tif			
source=Hemostatix to C2DX Assignment#page4.tif			
source=Hemostatix to C2DX Assignment#page5.tif			

CH \$40.00 2128414

**INTELLECTUAL PROPERTY ASSIGNMENT**

This INTELLECTUAL PROPERTY ASSIGNMENT (this “IP Assignment”), dated as of January 1, 2022, is made by Hemostatix Medical Technologies, LLC, a Tennessee limited liability company (“Assignor”), in favor and for the benefit of C2Dx, Inc., a Michigan corporation (“Assignee”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement (as defined below).

WHEREAS, pursuant to the terms of that certain Asset Purchase Agreement, of even date herewith (the “Purchase Agreement”), by and among Assignee, Assignor, Brad Beale and Jeff Cobb, the parties thereto have agreed, among other things, that Assignor will sell, transfer and convey to Assignee the Business IP, including, without limitation, all goodwill associated therewith and symbolized thereby; and

WHEREAS, the execution and delivery of this IP Assignment is required under Sections 2.10 and 2.11 of the Purchase Agreement.

NOW, THEREFORE, in consideration of the promises and of the respective agreements and conditions contained herein, Assignor and Assignee, intending to be legally bound, hereby agree as follows:

1. Assignor hereby irrevocably conveys, transfers and assigns to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and interest in and to the Business IP, including, without limitation:

(a) the patents, patent applications, trademarks, service marks, trademark applications, service mark applications, copyrights, copyright applications, trade names and domain names set forth on Exhibit A attached hereto;

(b) all rights of any kind whatsoever of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world;

(c) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing;

(d) all goodwill associated with the foregoing and symbolized thereby; and

(e) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Assignor hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks in the United States Patent and Trademark Office, and the Register of Copyrights

in the United States Copyright Office, and the officials of corresponding entities or agencies in any applicable jurisdictions, to record and register this IP Assignment upon request by Assignee. Following the date hereof, upon Assignee's reasonable request, Assignor shall take such steps and actions, and provide cooperation and assistance to Assignee and its successors, assigns and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documents, as may be reasonably necessary to effect, evidence or perfect the assignment of the Business IP to Assignee, or any assignee or successor thereto.

3. Nothing herein expressed or implied is intended to confer upon any Person, other than Assignee and Assignor and their respective successors and assigns, any rights, remedies, obligations or liabilities.

4. This IP Assignment may not be amended or modified in any respect, except by a written instrument signed by all the parties hereto making specific reference to this IP Assignment. This IP Assignment shall inure to the benefit of and be binding upon the parties and their respective successors and permitted assigns.

5. This IP Assignment may be executed in one or more counterparts, each of which will be deemed to be an original but all of which together will constitute one and the same document. The exchange of copies of this IP Assignment and of signature pages by facsimile transmission, by electronic mail in "portable document format" (".pdf") form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of such means, shall constitute effective execution and delivery of this IP Assignment as to the parties and may be used in lieu of the original IP Assignment for all purposes.

6. This IP Assignment is governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of laws principles.

7. If any term, provision or clause hereof, or of any other agreement or document which is required by this IP Assignment, is held to be invalid, such invalidity shall not affect or render invalid any other provision or clause hereof or thereof, all of which shall remain in full force and effect. If any provision of this IP Assignment is so broad as to be unenforceable, such provision shall be interpreted to be only as broad as is enforceable under applicable law.

8. Notwithstanding anything herein to the contrary, the provisions of this IP Assignment shall be subject to the provisions of the Purchase Agreement, and, if and to the extent the provisions of this IP Assignment are inconsistent in any way with the provisions of the Purchase Agreement, the provisions of the Purchase Agreement shall be controlling. Nothing contained herein shall be deemed to alter, modify, expand or diminish the terms and provisions set forth in the Purchase Agreement.

***[Signature Page Follows]***

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment as of the date first set forth above.

**ASSIGNEE:**

C2DX, INC.

By:  \_\_\_\_\_

Name: Kevin McLeod

Title: Chief Executive Officer

**ASSIGNOR:**

HEMOSTATIX MEDICAL TECHNOLOGIES,  
LLC

By: \_\_\_\_\_

Name: Brad Beale

Title: President

18908653

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment as of the date first set forth above.

**ASSIGNEE:**

C2DX, INC.

By: \_\_\_\_\_

Name: Kevin McLeod

Title: Chief Executive Officer

**ASSIGNOR:**

HEMOSTATIX MEDICAL TECHNOLOGIES,  
LLC

By:  \_\_\_\_\_

Name: Brad Beale

Title: President

18908653

[Signature Page to IP Assignment]

**TRADEMARK**  
**REEL: 008194 FRAME: 0048**

**EXHIBIT A**

**BUSINESS IP**

PATENT: 8,475,444 B2  
DATE OF PATENT: JULY 2, 2013  
DESCRIPTION: HEMOSTATIC SURGICAL BLADE SYSTEM AND METHOD  
INVENTOR: PHILIP E. EGGERS  
ASSIGNMENT: HEMOSTATIX MEDICAL TECHNOLOGIES, LLC

PATENT: 8,142,425 B2  
DATE OF PATENT: MARCH 27, 2012  
DESCRIPTION: HEATED SURGICAL BLADE, SYSTEM AND METHOD OF BLADE  
MANUFACTURE  
INVENTOR: PHILIP E. EGGERS  
ASSIGNMENT: HEMOSTATIX MEDICAL TECHNOLOGIES, LLC

PATENT: 11,219,480  
DATE OF PATENT: January 11, 2022  
DESCRIPTION: APPARATUS, SYSTEM AND METHOD FOR EXCISION FOR SOFT  
TISSUE  
INVENTOR: PHILIP E. EGGERS / BRAD BEALE  
ASSIGNMENT: HEMOSTATIX MEDICAL TECHNOLOGIES, LLC

PATENT FILING: SERIAL NO. 17/015609 (US PUBLICATION 2021/0077175)  
DATE OF FILING: SEPTEMBER 9, 2020  
DESCRIPTION: HEMOSTATIC SURGICAL BLADE, SYSTEM AND METHOD OF BLADE  
MANUFACTURE AND METHOD OF USE  
INVENTOR: PHILIP E. EGGERS / BRAD BEALE  
ASSIGNMENT: HEMOSTATIX MEDICAL TECHNOLOGIES, LLC

TRADEMARK: HEMOSTATIX  
REGISTRATION NO. 2128414  
REGISTRATION DATE: JULY 13, 1998  
DATE OF FIRST USE: AUGUST 1, 1994